FindTrial
Sign In

Pleiotropic effects of pravastatin, atorvastatin, and rosuvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia

Pleiotropic effects of pravastatin, atorvastatin, and rosuvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia - Pleiotropic effects of three statins

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000007264
Enrollment
120
Registered
2012-02-10
Start date
2008-09-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with type 2 diabetes mellitus and hypercholesterolemia

Interventions

pravastatin atorvastatin rosuvastatin

Sponsors

University of Occupational and Environmental Health, Japan, First Department of Internal Medicine, School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: patients with hypercholesterolemia and type 2 diabetes mellitus LDL-C level ≥100 mg/dL

Exclusion criteria

Exclusion criteria: patients with a history of stroke or ischemic heart disease during the previous 6 months patients with hepatopathy (alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) >80 IU/L) patients with nephropathy (serum creatinine >1.3 mg/dL) female patients who were pregnant or possibly pregnant

Design outcomes

Primary

MeasureTime frame
The primary endpoint was specified as achievement of the target LDL-C level (<80 mg/dL).—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026